



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/653,520	09/02/2003	Jonathon L. Kimmel	00138CIPCON(3600-360-01)	3339

7590 01/26/2007
Martha Ann Finnegan, Esq.
Cabot Corporation
157 Concord Road
Billerica, MA 01821-7001

EXAMINER

MAI, NGOCLAN THI

ART UNIT	PAPER NUMBER
----------	--------------

1742

MAIL DATE	DELIVERY MODE
-----------	---------------

01/26/2007

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

**Supplemental to
Notice of Allowability**

Application No.

10/653,520

Examiner

Ngoclan T. Mai

Applicant(s)

KIMMEL ET AL.

Art Unit

1742

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address--

All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. **THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS.** This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.

1. ☒ This communication is responsive to missing of claim 164.
2. ☒ The allowed claim(s) is/are 28-39, 41, 47-55, 57, 58, 60, 61, 63, 64, 66, 67, 69, 70, 72, 73, 75, 76, 78, 79, 81, 82, 84, 85, 87, 88, 90, 91, 95-97, 113-125, 136-154, 157-167 (Note that claims 165-168 have been renumbered as 164-167, per 37 C.F.R. 1.126).

3. ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).

a) ☐ All b) ☐ Some* c) ☐ None of the:

1. ☐ Certified copies of the priority documents have been received.

2. ☐ Certified copies of the priority documents have been received in Application No. _____.

3. ☐ Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

* Certified copies not received: _____.

Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application.

THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.

4. ☐ A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.
5. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted.
- (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached
- 1) ☐ hereto or 2) ☐ to Paper No./Mail Date _____.
- (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date _____.

Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d).

6. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.

Attachment(s)

- | | |
|---|---|
| 1. <input type="checkbox"/> Notice of References Cited (PTO-892) | 5. <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 2. <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 6. <input type="checkbox"/> Interview Summary (PTO-413),
Paper No./Mail Date _____ |
| 3. <input type="checkbox"/> Information Disclosure Statements (PTO-1449 or PTO/SB/08),
Paper No./Mail Date _____ | 7. <input type="checkbox"/> Examiner's Amendment/Comment |
| 4. <input type="checkbox"/> Examiner's Comment Regarding Requirement for Deposit
of Biological Material | 8. <input type="checkbox"/> Examiner's Statement of Reasons for Allowance |
| | 9. <input type="checkbox"/> Other _____ |

ROY KING

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1700

U.S. Patent Application No. 10/653,520
Amendment dated July 5, 2006
Reply to Office Action dated May 18, 2006

wherein said oxygen-reduced niobium oxide has the formula Nb_xO_y wherein x is 1 and y is 0.7 to 1.1.

163. (Previously presented) The oxygen-reduced niobium oxide particles of claim 122, wherein said oxygen-reduced niobium oxide has the formula Nb_xO_y wherein x is 1 and y is 0.7 to less than 2.

Renumbered 37 CFR 1.126 164. ~~165.~~ (Previously presented) The oxygen-reduced niobium oxide particles of claim 122, wherein said oxygen-reduced niobium oxide has the formula Nb_xO_y wherein x is 1 and y is 0.7 to 1.1.

165. ~~166.~~ (Previously presented) The oxygen-reduced niobium oxide particles of claim 124, wherein said oxygen-reduced niobium oxide has the formula Nb_xO_y wherein x is 1 and y is 0.7 to less than 2.

166. ~~167.~~ (Previously presented) The agglomerated oxygen-reduced valve metal oxide of claim 97, wherein said agglomerated particles are formed from oxygen-reduced niobium oxide particles having an average primary particle size of from 1 micron to 10.5 microns.

167. ~~168.~~ (Previously presented) The oxygen-reduced niobium oxide particles of claim 113, wherein said oxygen-reduced niobium oxide particles have a primary particle size of from 1 micron to 10.5 microns and are agglomerated and have agglomerate sizes of less than 425 microns.